Prof. Jing Huang 黄镜
Chief Physician, Professor
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gastrointestinal tumors, lung cancer, breast cancer, urogenital tumors, head and neck tumors, and lymphoma.
Dr. Huang is Deputy Director of Medical Oncology at the Cancer Hospital, Chinese Academy of Medical Sciences. After graduating in 1989 and earning a medical doctorate in 1997, Dr. Huang completed postdoctoral training at the US National Cancer Institute (1998–2000). Dr. Huang has led multiple Phase 1–3 clinical trials and contributed to research awarded the National Science and Technology Progress Award (First Class).
Professional roles
- Vice Chair and Secretary-General, Esophageal Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Tumor Rehabilitation Branch, China Gerontology and Geriatrics Association
- Standing Committee Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Deputy Editor-in-Chief, Chinese Journal of Biochemical Pharmaceuticals
Name order: in Chinese the family name comes first (Huang Jing). Papers usually list the name as Jing Huang or Huang J.
Selected publications
20 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Precis Radiat Oncol, 2026 (first author): R3Net: Recursive Residual Refinement Network Architecture for Decoder-Free Medical Image Segmentation. PubMed 42540339
- Respir Res, 2025 (first author): Exploring a mutation-based signature to predict the benefits of immune checkpoint inhibitors in oncogene-addicted subsets of non-small cell lung cancer: a retrospective study. PubMed 41275227
- J Immunother Cancer, 2025 (senior author): Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial. PubMed 41167638
- Cancer Commun (Lond), 2024 (senior author): HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. PubMed 39446605
- Respir Res, 2024 (first author): Comprehensive analysis reveals the prognostic and immunogenic characteristics of DNA methylation regulators in lung adenocarcinoma. PubMed 38317133
- Cell Rep Med, 2023 (senior author): Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. PubMed 38016482
- Cancer Med, 2023 (senior author): Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer. PubMed 36341590
- Thorac Cancer, 2021 (senior author): SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. PubMed 33760397
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion